Latest Conference Articles

Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.

Aime T. Franco, PhD, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.

The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.

During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.

At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.

At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.

Aaron Logan, MD, PhD, discusses some of the treatment options available for patients with acute lymphoblastic leukemia.

At a 2022 NCCN meeting, a panel discussed the use of immunotherapy for the treatment of patients with multiple myeloma, specifically how to choose the best course of action and how to manage toxicities.

At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.

Bijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.

Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.

In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.

Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.

When choosing a treatment regimen for follicular lymphoma, an individualized approach is necessary, according to Loretta J. Nastoupil, MD.

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.

Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.

AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.

Chimeric antigen receptor T-cell therapy provides a new option for patients with relapsed/refractory B-cell lymphoma.

Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.

During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.

Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.

Novel therapies for cutaneous T-cell lymphoma novel therapies for this patient population are helping to create straightforward management strategies.

The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.

Interim findings from the DREAMM-6 study hint that belantamab mafodotin plus lenalidomide and dexamethasone is effective with tolerable safety in patients with relapsed or refractory multiple myeloma.

Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Haris Ali, MD, explored the potential role of disease-modifying agents on transplant indications in this setting during the 10th Annual Meeting of the Society of Hematologic Oncology

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.

While tyrosine kinase inhibitors the current standard of care for most patients with CML, investigators may need to look at new options and combinations for those with TKI resistance.